News | Prostate Cancer | October 04, 2017

Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT

Results presented at 2017 ASTRO Annual Meeting evaluate clinical utility of fluciclovine (18F) PET/CT imaging in men with recurrent prostate cancer following prior treatment

Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT

October 4, 2017 — Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational clinical trial evaluating the impact of fluciclovine (18F) PET/CT imaging on clinical management of men with biochemically recurrent prostate cancer eligible for salvage therapy.

The FALCON trial is a U.K.-based, prospective, multi-center, open-label study (NCT02578940) to evaluate the clinical impact of fluciclovine (18F) positron emission tomography/computed tomography (PET/CT) imaging on patient management decisions in men with biochemically recurrent prostate cancer. The primary endpoint of the FALCON study examines the percentage of men who have their management plan changed after a F-18 PET/CT scan. Blue Earth Diagnostics previously announced a halt to patient recruitment for the trial based on successful results of a pre-planned interim analysis.

Axumin (fluciclovine F-18 injection) is a U.S. Food and Drug Administration (FDA)-approved molecular imaging agent for use in PET imaging in men with suspected prostate cancer recurrence based on elevated blood levels of prostate specific antigen (PSA) following prior treatment. It is not currently approved in the United States for treatment planning in men with biochemically recurrent prostate cancer.

The FALCON trial recorded intended patient management plans prior to fluciclovine (18F) PET/CT and then recorded how they were altered once patients and their clinicians had results of the scan. Results of the interim analysis showed that 61.2 percent (52/85) of patients had their clinical management changed when results of fluciclovine (18F) PET/CT imaging were added to the standard-of-care diagnostic work-up. The interim results were presented in an oral presentation, “Impact of 18F-fluciclovine PET/CT on clinical management of patients with recurrent prostate cancer: results from the Phase III FALCON trial,” by Eugene Teoh, M.D., Oxford University Hospitals NHS Foundation Trust, at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24 – 27 in San Diego.

The FALCON trial enrolled men with a biochemical recurrence of prostate cancer being considered for curative intent salvage therapy. Intended management plans were recorded prior to fluciclovine (18F) PET/CT imaging and then compared with post-scan plans. The primary endpoint examined the percentage of men who had their management plan changed after a fluciclovine (18F) scan. A single, pre-planned analysis of the primary endpoint for efficacy or futility was performed based on the first 85 evaluable patients. Based on this analysis, recruitment in the trial was stopped for efficacy. Previously planned therapeutic management was revised after a fluciclovine (18F) PET/CT scan in 61.2 percent (52/85) of patients. Of the 52 patients with revised treatment plans, major revisions (e.g., salvage radiotherapy to hormone deprivation or watchful waiting) were made for 59.6 percent (31/52) of patients. Salvage treatment was revised to watchful waiting for 25 percent (13/52) of patients and to systemic therapy for 34.6 percent (18/52) of patients, while 40.4 percent (21/52) of patients had their previously planned radiotherapy field modified. The safety profile of fluciclovine (18F) in the FALCON trial is consistent with that described in the approved U.S. Prescribing Information.

“Biochemically recurrent prostate cancer poses an important medical challenge,” said Abhishek Solanki, M.D., assistant professor of radiation oncology, Loyola University School of Medicine, Chicago. “Currently approved anatomical imaging procedures have limitations in identifying the sites of recurrence of prostate cancer after definitive treatment, which can make decision-making difficult when assessing patients with biochemical recurrence. Newer imaging techniques, such as fluciclovine (18F) PET/CT, may provide actionable information for physicians in guiding appropriate patient management.”

“Selecting appropriate patient care options for men with biochemically recurrent prostate cancer is critical,” said Judd Moul, M.D., professor of surgery, urology, at Duke University. “Many options are available, and some patient management plans may carry uncertainty that could potentially be alleviated by more accurate information. Clinical studies are important to investigate the role that reliable information provided by diagnostic imaging can play in guiding appropriate management for men with recurrent prostate cancer.”

Blue Earth Diagnostics has also updated the status of its investigational LOCATE study (“The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients with Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment”), which completed patient enrollment earlier than anticipated. Compilation of data from the 15 clinical sites is currently underway, with results planned for peer-reviewed presentation and publication next year. The LOCATE trial is a U.S. multi-center study investigating the impact on patient management of 18F fluciclovine PET/CT imaging in patients with rising PSA after initial prostate cancer treatment. The clinical utility of 18F fluciclovine PET/CT imaging will be assessed by the change from initial to revised treatment plan.

For more information: www.blueearthdiagnostics.com

Related Content

ringing the cancer bell can do more harm than good, says an ASTRO study

Image courtesy of ASTRO

News | Radiation Oncology | January 27, 2020
January 27, 2020 — It's a scene that some cancer patients dream about: they celebrate the end of a course of radiatio
A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast

A 50-y-old postmenopausal woman with fibroadenoma (arrows) in left breast. (A) Unenhanced fat-saturated T1-weighted MRI shows extreme amount of FGT (ACR d). (B) Moderate BPE is seen on dynamic contrast-enhanced MRI at 90 s. (C) Mean ADC of breast parenchyma of contralateral breast on diffusion-weighted imaging with ADC mapping is 1.5 × 10?3 mm2/s. (D) On 18F-FDG PET/CT, lesion is not 18F-FDG-avid, and BPU of normal breast parenchyma is relatively high, with SUVmax of 3.2. Photo courtesy of K Pinker, et al., Medical University of Vienna, Vienna, Austria

News | PET-MRI | January 27, 2020
January 27, 2020 — Researchers have identified several potentially useful...
Nuclear imaging of the spine shown on Philips Healthcare BrightView XCT

Image courtesy of Philips Healthcare

News | Nuclear Imaging | January 27, 2020
January 27, 2020 — According to the new market research report "...
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha